摘要:
Glucagon peptides that exhibit GIP agonist activity in addition to glucagon and/or GLP-I activity are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided.
摘要:
Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.
摘要:
Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.
摘要:
Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.
摘要:
Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided.
摘要:
The present invention discloses an apparatus for baking a glass substrate, which includes: a baking oven, a support component, a temperature sensing device, a heating device, a cooling device, and a temperature controlling device. The present invention further discloses a method for baking a glass substrate. The present invention is capable of dynamically controlling the temperature of the support component, which contacts the glass substrate. The temperature of the glass substrate keeps identical and the temperature of the support component keep identical, so as to prevent a Mura defect appearing on the glass substrate.
摘要:
A liquid crystal panel includes a liquid crystal layer and a substrate. The substrate includes a sealant bonding area, a cutting edge surrounding the sealant bonding area, and an abutting portion disposed between the sealant bonding area and the cutting edge. A height of the abutting portion is less than a thickness of the liquid crystal layer. The present disclosure further provides a manufacturing method of the liquid crystal panel. With the abutting portion disposed outside the sealant, the uncured sealant is limited from flowing to the cutting edge during the process of bonding the TFT substrate and the CF substrate. Thus, the manufacturing process of the liquid crystal panel may not be influenced by the uncured sealant, and the distance L between the sealant and the cutting edge can be shortened to improve the coating precision of the sealant and the utilization rate of the substrate.
摘要:
A liquid crystal (LC) injection device is disclosed in the present invention and includes an LC container, a transporting pipe, a filter and an LC extractor. An inner wall of a bottom in the LC container is a concave shape. The transporting pipe is disposed within the LC container and contacted the inner wall of the bottom in the LC container. The present invention also discloses an LC container. The present invention is to increase the utilization efficiency of the LC container, decrease the LCs waste and enhance the accuracy of the measurement of the remaining LC quantity in the LC bottle.
摘要:
A liquid crystal panel includes a liquid crystal layer and a substrate. The substrate includes a sealant bonding area, a cutting edge surrounding the sealant bonding area, and an abutting portion disposed between the sealant bonding area and the cutting edge. A height of the abutting portion is less than a thickness of the liquid crystal layer. The present disclosure further provides a manufacturing method of the liquid crystal panel. With the abutting portion disposed outside the sealant, the uncured sealant is limited from flowing to the cutting edge during the process of bonding the TFT substrate and the CF substrate. Thus, the manufacturing process of the liquid crystal panel may not be influenced by the uncured sealant, and the distance L between the sealant and the cutting edge can be shortened to improve the coating precision of the sealant and the utilization rate of the substrate.
摘要:
A method and a device for recording media are provided. The method includes performing a media recording process. During the media recording process, periodically media index information are generated according to currently written media chunks. The generated media index information is saved.